DelveInsight’s, “Metastatic Urothelial Carcinoma Pipeline Insight, 2023” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Metastatic Urothelial Carcinoma pipeline landscape. It covers the Metastatic Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Metastatic Urothelial Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Metastatic Urothelial Carcinoma NDA approvals (if any), and product development activities comprising the technology, Metastatic Urothelial Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Metastatic Urothelial Carcinoma Pipeline Report
- DelveInsight’s Metastatic Urothelial Carcinoma pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Metastatic Urothelial Carcinoma treatment.
- The leading Metastatic Urothelial Carcinoma Companies includes PharmaMar, Ectin Research AG, Exelixis, Eli Lilly and Company, Merck Sharp & Dohme LLC, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc., and others.
- Promising Metastatic Urothelial Carcinoma Pipeline Therapies includes Enfortumab vedotin, Pembrolizumab, AGS15E, Atezolizumab 1200 mg/m2, Gemcitabine 1000 mg/m2, Epacadostat, Atezolizumab, Carboplatin, Gemcitabine, Rogaratinib (BAY1163877), Chemotherapy, and others.
- The Metastatic Urothelial Carcinoma companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Urothelial Carcinoma R&D. The Metastatic Urothelial Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Metastatic Urothelial Carcinoma.
To explore more information on the latest breakthroughs in the Metastatic Urothelial Carcinoma Pipeline treatment landscape of the report, click here @ Metastatic Urothelial Carcinoma Pipeline Outlook
Metastatic Urothelial Carcinoma Overview
Urothelial carcinoma is the sixth most common malignancy in the US. Bladder cancer (with urothelial carcinoma accounting for 90% of bladder tumors in the USA) is the most common malignancy of the urinary tract system and the sixth most common cancer in the USA, with an estimated 79,030 cases to be diagnosed in 2017. Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is by far the most common type of bladder cancer. In fact, if a person have bladder cancer it's almost certain to be a urothelial carcinoma. These cancers start in the urothelial cells that line the inside of the bladder. Urothelial cells also line other parts of the urinary tract, such as the part of the kidney that connects to the ureter (called the renal pelvis), the ureters, and the urethra. People with bladder cancer sometimes have tumors in these places, too, so all of the urinary tract needs to be checked for tumors. Other types of cancer can start in the bladder, but these are all much less common than urothelial (transitional cell) cancer.
Metastatic Urothelial Carcinoma Emerging Drugs Profile
MFA 370: Ectin Research AG
Urothelial bladder cancer is one of the world’s most aggressive cancers, current treatments can be tough to tolerate. MFA-370 is planned to be a simple oral tablet developed to eliminate tumors safely, with few if any side effects. MFA-370 is a combination of a medication from that substance family, together with one other standard, well-established drug. Both are tried, tested and trusted treatments that have already undergone large-scale clinical trials. It already demonstrated efficacy in preclinical results and ‘patient zero’ case. In addition to MFA-370 showing positive preclinical results in metastatic urothelial bladder cancer, it has also eliminated prostate, breast and colorectal cancer cells in preclinical tests too. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Metastatic Urothelial Carcinoma.
XL 092: Exelixis
XL092 is a next-generation oral TKI that builds on our extensive experience with cabozantinib. XL092 also targets VEGF receptors, MET, TAM kinases and other kinases implicated in cancer’s growth and spread. In preclinical tumor models, XL092 showed excellent activity as a single agent and in combination with ICIs. XL092 also has an optimized pharmacokinetic profile aimed at facilitating adverse event management in the clinic. XL092 is the first new Exelixis-discovered compound to come out of the company’s reinitiated drug discovery activities, which entered phase 1 clinical development in 2019. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic Urothelial Carcinoma.
Lurbinectedin: PharmaMar
Lurbinectedin, also known as PM01183, or commercially where approved as Zepzelca® is an analogue of a similar natural compound ET-736 with characteristics that make it similar but different to its parent compounds. Lurbinectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Metastatic Urothelial Carcinoma.
For further information, refer to the detailed Metastatic Urothelial Carcinoma Unmet Needs, Metastatic Urothelial Carcinoma Market Drivers, and Market Barriers, click here for Metastatic Urothelial Carcinoma Ongoing Clinical Trial Analysis
Metastatic Urothelial Carcinoma Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the therapies for Metastatic Urothelial Carcinoma. The companies which have their Metastatic Urothelial Carcinoma drug candidates in the most advanced stage, i.e. phase II include, PharmaMar.
Metastatic Urothelial Carcinoma Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Request a sample and discover the recent advances in Metastatic Urothelial Carcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Urothelial Carcinoma Treatment Landscape
Scope of the Metastatic Urothelial Carcinoma Pipeline Report
- Coverage- Global
- Metastatic Urothelial CarcinomaCompanies- PharmaMar, Ectin Research AG, Exelixis, Eli Lilly and Company, Merck Sharp & Dohme LLC, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc., and others.
- Metastatic Urothelial CarcinomaPipeline Therapies- Enfortumab vedotin, Pembrolizumab, AGS15E, Atezolizumab 1200 mg/m2, Gemcitabine 1000 mg/m2, Epacadostat, Atezolizumab, Carboplatin, Gemcitabine, Rogaratinib (BAY1163877), Chemotherapy, and others.
- Metastatic Urothelial Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Metastatic Urothelial Carcinoma Market Drivers and Metastatic Urothelial Carcinoma Market Barriers, click here @ Metastatic Urothelial Carcinoma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Metastatic Urothelial Carcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic Urothelial Carcinoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Lurbinectedin: PharmaMar
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- XL 092: Exelixis
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name : Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Metastatic Urothelial Carcinoma Key Companies
- Metastatic Urothelial Carcinoma Key Products
- Metastatic Urothelial Carcinoma- Unmet Needs
- Metastatic Urothelial Carcinoma- Market Drivers and Barriers
- Metastatic Urothelial Carcinoma- Future Perspectives and Conclusion
- Metastatic Urothelial Carcinoma Analyst Views
- Metastatic Urothelial Carcinoma Key Companies
- Appendix
Got Queries? Find out the related information on Metastatic Urothelial Carcinoma Mergers and acquisitions, Metastatic Urothelial Carcinoma Licensing Activities @ Metastatic Urothelial Carcinoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
